ライフサイエンスコーパス: pelvic organ prolapse

1 arity was also significantly associated with pelvic organ prolapse.

2 ue in women undergoing a first operation for pelvic organ prolapse.

3 nd fibrosis in parous women with symptomatic pelvic organ prolapse.

4 e pelvic organs and loss of support leads to pelvic organ prolapse.

5 c organ prolapse compared with those without pelvic organ prolapse.

6 performed annually in the United States for pelvic organ prolapse.

7 o discuss the epidemiology and prevalence of pelvic organ prolapse.

8 revention in patients at risk for developing pelvic organ prolapse.

9 transvaginal mesh kits for the treatment of pelvic organ prolapse.

10 s has been implicated in the pathogenesis of pelvic organ prolapse.

11 al pelvic floor for defecatory disorders and pelvic organ prolapse.

12 have increased the available treatments for pelvic organ prolapse.

13 9% of women (95% CI, 2.1%-3.7%) experiencing pelvic organ prolapse.

14 important components in the pathogenesis of pelvic organ prolapse.

15 ions in lysyl oxidase-like 1 (LOXL1) develop pelvic organ prolapse.

16 nt of female stress urinary incontinence and pelvic organ prolapse.

17 in repair of stress urinary incontinence and pelvic organ prolapse.

18 rinary incontinence, fecal incontinence, and pelvic organ prolapse) affect many women.

19 Among patients with symptomatic pelvic organ prolapse, an initial strategy of pessary th

20 related to abnormal elastic fibers, such as pelvic organ prolapse and cardiovascular and pulmonary a

21 rformed to determine the association between pelvic organ prolapse and exfoliation syndrome in women

22 ant proven benefit for symptomatic relief of pelvic organ prolapse and improvement of quality of life

23 free vaginal tape was examined in women with pelvic organ prolapse and older in age.

24 a sample of women who screened positive for pelvic organ prolapse and other urinary incontinence sym

25 Pelvic floor disorders, including pelvic organ prolapse and urinary and fecal incontinence

26 g pelvic floor surgery including surgery for pelvic organ prolapse and urinary incontinence.

27 of conditions affecting adult women, include pelvic organ prolapse and urinary incontinence.

28 Many women with pelvic organ prolapse are asymptomatic and do not need t

29 incontinence undergoing vaginal surgery for pelvic-organ prolapse are at risk for postoperative urin

30 te outcome of success, defined as absence of pelvic organ prolapse beyond the hymen in any compartmen

31 than 90% of fibulin-5-knockout mice develop pelvic organ prolapse by 20 weeks of age.

32 ther the rate of transvaginal mesh repair of pelvic organ prolapse changed after US Food and Drug Adm

33 of life impact of PFD, total and by domain (pelvic organ prolapse, colorectal-anal, and urogenital).

34 the exfoliation syndrome risk in women with pelvic organ prolapse compared with those without pelvic

35 The surgical management of pelvic organ prolapse continues to evolve.

36 bdominal sacrocolpopexy for the treatment of pelvic-organ prolapse decreases postoperative stress uri

37 en aged 30 to 65 years at baseline who had a pelvic organ prolapse diagnosis compared with controls d

38 The symptomatic coprimary outcome was the Pelvic Organ Prolapse Distress Inventory (POPDI) symptom

39 mes at 2 years were prolapse symptom scores (Pelvic Organ Prolapse Distress Inventory; range 0-300, h

40 omain (P = 0.0005, 95% CI: 3.8-13.5) and the pelvic organ prolapse domain (P = 0.015, 95% CI: 0.6-9.5

41 in the uterine tract post partum and develop pelvic organ prolapse, enlarged airspaces of the lung, l

42 cells obtained from women with uterovaginal pelvic organ prolapse following vaginal hysterectomy.

43 trials that included surgical operations for pelvic organ prolapse for this review.

44 Postmenopausal women with symptomatic pelvic organ prolapse >=stage 2 and successfully fitted

45 o the assessment of defecatory disorders and pelvic organ prolapse has highlighted the limitations of

46 irth control and a surgical mesh implant for pelvic organ prolapse, have led to calls to reexamine th

47 Pelvic organ prolapse in Fbln5-/- mice was remarkably si

48 life expectancy increases, the prevalence of pelvic organ prolapse in general, and rectoceles, in par

49 genic organizer, fibulin-5 (FBLN5), leads to pelvic organ prolapse in mice.

50 is is a primary event in the pathogenesis of pelvic organ prolapse in mice.

51 ion syndrome was more frequent in women with pelvic organ prolapse in the Utah Population Database, a

52 ific quantificative information about female pelvic organ prolapse-information that usually can only

53 Pelvic organ prolapse is a common connective tissue diso

54 Pelvic organ prolapse is a prevalent condition among wom

55 Pelvic organ prolapse is closely related to SUI, and the

56 Pelvic organ prolapse is common and is strongly associat

57 Pelvic organ prolapse is downward descent of female pelv

58 Pelvic organ prolapse is strongly associated with a hist

59 with obstetrical trauma is a risk factor for pelvic organ prolapse later in life.

60 thought to be involved in the development of pelvic organ prolapse may also be linked to the developm

61 ditions with altered ECM metabolism, such as pelvic organ prolapse, may share common biological pathw

62 d women serving as controls who did not have pelvic organ prolapse (n = 15338).

63 to 65 years at baseline with a diagnosis of pelvic organ prolapse (n = 5130) compared with birth yea

64 full understanding of the complex impact of pelvic organ prolapse on lower urinary tract function is

65 creased risk of the woman having surgery for pelvic organ prolapse or urinary incontinence (aHR 3.17,

66 lastic fiber assembly in the pathogenesis of pelvic organ prolapse, pelvic organ support was characte

67 nrolled twenty-two postmenopausal women with pelvic organ prolapse planning to undergo vaginal hyster

68 rders, a large portion of which will involve pelvic organ prolapse (POP) and lower urinary tract dysf

69 for the fibulin-5 gene (Fbln5(-/-)) develop pelvic organ prolapse (POP) due to compromised elastic f

70 Sow mortality attributable to pelvic organ prolapse (POP) has increased in the U.S. sw

71 ent of stress urinary incontinence (SUI) and pelvic organ prolapse (POP) have produced highly variabl

72 Pelvic organ prolapse (POP) is a common condition affect

73 Pelvic organ prolapse (POP) is a common condition that c

74 Pelvic organ prolapse (POP) is a common, debilitating di

75 Pelvic organ prolapse (POP) is a disabling disorder in w

76 Mesh, a synthetic graft, has been used in pelvic organ prolapse (POP) repair and stress urinary in

77 PURPOSE OF REVIEW: Mesh used for slings and pelvic organ prolapse (POP) repair has resulted in incre

78 y have continually adapted new techniques in pelvic organ prolapse (POP) repair in order to improve b

79 uation of the use of commercial mesh kits in pelvic organ prolapse (POP) repair.

80 rictions on postoperative activity following pelvic organ prolapse (POP) surgery are not evidence bas

81 ublished data concerning the indications for pelvic organ prolapse (POP) surgery in women who present

82 OF REVIEW: As more women undergo repairs of pelvic organ prolapse (POP), an ever-increasing scrutiny

83 0 codes) for PFD [urinary incontinence (UI), pelvic organ prolapse (POP), and bowel dysfunction (anal

84 for pelvic floor disorders (PFDs), including pelvic organ prolapse (POP), stress urinary incontinence

85 tegrity or biomechanical function may induce pelvic organ prolapse (POP).

86 sed vaginal mechanical integrity can lead to pelvic organ prolapse (POP).

87 performed annually in the United States for pelvic organ prolapse (POP).

88 nimally invasive surgery in the treatment of pelvic organ prolapse (POP); however, the robotic indust

89 ity; homozygosity for Loxl1 mutations led to pelvic organ prolapse, preventing aging.

90 hile the introduction of novel approaches to pelvic organ prolapse provide further options when consi

91 natomic POP failure requiring retreatment or Pelvic Organ Prolapse Quantification evaluation demonstr

92 f pelvic organ support loss according to the Pelvic Organ Prolapse Quantification System (noninferior

93 anterior prolapse (of stage 2 or higher on a Pelvic Organ Prolapse Quantification system examination)

94 Using the Pelvic Organ Prolapse Quantification system, researchers

95 mesh use in stress urinary incontinence and pelvic organ prolapse repair are examined.

96 search (basic and clinical) are post-MUS and pelvic organ prolapse repair urinary retention and obstr

97 y become the preferred approach to abdominal pelvic organ prolapse repair.

98 outcomes of different vaginal approaches to pelvic organ prolapse repair.

99 able using minimally invasive techniques for pelvic organ prolapse repair.

100 ry vulnerable to surgical techniques used in pelvic organ prolapse repair.

101 kage of solid, liquid, or mucous stool), and pelvic organ prolapse (seeing/feeling a bulge in or outs

102 success 2 years after primary uterus-sparing pelvic organ prolapse surgery for uterine descent, these

103 Defining a successful outcome of pelvic organ prolapse surgery from a symptomatic perspec

104 RECENT FINDINGS: Success in pelvic organ prolapse surgery has been redefined.

105 h require a review of vaginal approaches for pelvic organ prolapse surgery with and without mesh.

106 out how to define a successful outcome after pelvic organ prolapse surgery.

107 icipant-reported prolapse symptoms (i.e. the Pelvic Organ Prolapse Symptom Score [POP-SS]) and condit

108 ie, a significantly greater reduction in the pelvic organ prolapse symptom score [POP-SS]) at 12 mont

109 outcome was self-reported prolapse symptoms (Pelvic Organ Prolapse Symptom Score [POP-SS]) at 2 years

110 of concomitant conditions, such as advanced pelvic organ prolapse, that may require referral.

111 group vs 0 of 97 in the radiotherapy group), pelvic organ prolapse (three [3%] vs 0), fatigue, hot fl

112 ary self-management vs clinic-based care for pelvic organ prolapse (TOPSY): a randomised controlled s

113 Pelvic organ prolapse, urinary, bowel and sexual dysfunc

114 es in genital hiatus (GH) and development of pelvic organ prolapse using data from the Mothers' Outco

115 association between exfoliation syndrome and pelvic organ prolapse using the Utah Population Database

116 surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh.

117 Pelvic organ prolapse was associated with a 1.56-fold in

118 ndrome (exfoliation of the lens capsule) and pelvic organ prolapse was investigated as part of the Ut

119 ersy regarding the use of synthetic mesh for pelvic organ prolapse, we did a retrospective review of

120 ho will present to healthcare providers with pelvic organ prolapse, we need a better understanding of

121 elastic fibers after parturition, leading to pelvic organ prolapse, weakening of the vaginal wall, pa

122 ontinence (11%), non-injury wounds (9%), and pelvic organ prolapse were also prevalent.

123 05 women with symptomatic stage 2 or greater pelvic organ prolapse were requested to participate betw

124 pected to double in number by the year 2030, pelvic organ prolapse will become more prevalent.

125 need for cost-effective care for women with pelvic organ prolapse will continue to increase.

126 t exfoliation syndrome risk in patients with pelvic organ prolapse (without exfoliation syndrome hist